Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | BDKRB1 | P46663 | 9/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823349 | 0.84 | KDR (0.60) | KDRBDKRB1 | |
| SCHEMBL6542710 | 0.83 | KDR (0.62) | KDRBDKRB1 | |
| Hydrochloric Acid SCHEMBL7832291 | 0.82 | KDR (0.59) | KDRBDKRB1 | |
| SCHEMBL6543759 | 0.82 | BDKRB1 (0.48) | KDRBDKRB1 | |
| SCHEMBL5871444 | 0.82 | PKM (0.58) | KDRBDKRB1 | |
| SCHEMBL1490693 | 0.81 | KIT (0.48) | KDRBDKRB1 | |
| SCHEMBL6542481 | 0.80 | KDR (0.45) | KDRBDKRB1 | |
| SCHEMBL6542903 | 0.79 | ALDH1A1 (0.58) | KDRBDKRB1 | |
| SCHEMBL18071001 | 0.79 | MAPT (0.65) | KDRBDKRB1 | |
| SCHEMBL427718 | 0.77 | KDR (0.62) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| CN-101056870-A | Nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1807416-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | KDR 2/4885BDKRB1 107/4885CNR2 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.